Abstract library

5 results for "Mahvash".
#1253 A Novel Hereditary Pancreatic Neuroendocrine Tumor Syndrome Associated with Biallelic Inactivation of the Glucagon Receptor
Introduction: Hereditary pancreatic neuroendocrine tumors (PanNETs) are associated with 4 known autosomal dominant syndromes including MEN1, vHL disease, NF1, and TS. Glucagon receptor (GCGR) inactivation in human (Mahvash disease) has been associated with asymptomatic hyperglucagonemia, α-cell hyperplasia, and PanNET, and may represent a new hereditary syndrome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr. Laura Tang
Authors: Tang L, Yu R
#1256 Characterization and Rescue of a Pathogenic D63N Mutant Human Glucagon Receptor That Causes a Pancreatic Neuroendocrine Tumor Syndrome (Mahvash disease)
Introduction: We have previously demonstrated that inactivating glucagon receptor (GCGR) mutations cause a novel hereditary human disease of hyperglucagonemia, pancreatic α cell hyperplasia, and pancreatic neuroendocrine tumor (Mahvash disease). We recently identified a novel missense GCGR mutation, D63N, in a family with Mahvash disease.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr. Run Yu
Authors: Yu R, Zhou C, Chen C R
#1683 International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with Yttrium-90 Resin Microspheres
Introduction: Radioembolization (RE) is applied worldwide in patients with liver-dominant metastatic neuroendocrine tumours (mNET). Current literature is of poor quality and based on small heterogeneous populations
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: M.D. Arthur Braat
#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Arthur Braat
#2165 A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors
Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Assistant Profes Arvind Dasari